Dupilumab had a fivefold improvement in sustained disease remission in bullous pemphigoid compared with placebo, along with a significant reduction in oral corticosteroid use.

The U.S. Food and Drug Administration (FDA) has approved Dupixent (dupilumab) injections as an add-on therapy for adults with chronic obstructive pulmonary disease (COPD) who continue to struggle ...

randomized to 300 mg of subcutaneous dupilumab or a placebo injection every 2 weeks. At 36 weeks, 20% of those treated with dupilumab achieved the primary endpoint of sustained disease remission ...

At that time Sanofi was cruising towards an important FDA approval for its Dupixent (dupilumab) injection for the skin disease also known as atopic dermatitis. Noting the blockbuster potential for ...

Dupilumab and tralokinumab treat atopic dermatitis ... You give it to yourself as an injection under the skin every other week or once a month. Your doctor will prescribe either a prefilled ...

Five times more adults on Dupixent achieved sustained disease remission at 36 weeks compared to placebo; significant reductions were also seen in ...

for Dupixent ® (dupilumab) to treat adults with bullous pemphigoid (BP). The sBLA is supported by data from a pivotal trial evaluating the efficacy and safety of Dupixent in 106 adults with ...

In one study, a handful of people who took Dupixent (dupilumab) by injection had an eczema flare after being vaccinated for ...

SAN DIEGO — Adolescents and adults with eosinophilic esophagitis improved with dupilumab regardless of whether they were practicing food elimination diets during treatment, according to a poster ...

1 Dupilumab is being jointly developed by Regeneron ... Use DUPIXENT exactly as prescribed by your healthcare provider. It’s an injection given under the skin (subcutaneous injection).

1 Dupilumab is being jointly developed by Regeneron ... Use DUPIXENT exactly as prescribed by your healthcare provider. It’s an injection given under the skin (subcutaneous injection).